. Trial data support dexamethasone, but not hydroxychloroquine, for COVID-19 - IOPAC Press "Enter" to skip to content

The first-ever global oral health conference highlights universal health coverage by 2030
- All WHO news
Delegations from over 110 countries are coming together to produce national roadmaps and negotiate a joint declaration on oral health...
Lebanon: a conflict particularly destructive to health care
- All WHO news
Since 7 October 2023, 47% of attacks on health care – 65 out of 137 – have proven fatal to...
WHO adds LC16m8 mpox vaccine to Emergency Use Listing
- All WHO news
The World Health Organization (WHO) has granted Emergency Use Listing (EUL) for the LC16m8 mpox vaccine, making it the second...

The right to health
- WHO Director-General speeches
Excellencies, ladies and gentlemen, Good afternoon, and thank you for having me. It’s a real honour to be with you...
Closing address at High-Level Action Day, First WHO Global Conference on Air Pollution and Health
- WHO Director-General speeches
Every human being is entitled to breathe clean air. It’s a human right. We are honoured to have the Human...
Opening address at the First WHO Global Conference on Air Pollution and Health
- WHO Director-General speeches
Excellency, second Lady Hajia Samira Bawumia of Ghana, my colleague colleague Dr Taalas, Secretary General of WMO and my sister...

Trial data support dexamethasone, but not hydroxychloroquine, for COVID-19

By iopac on July 17, 2020

Chris Dall | News Reporter | CIDRAP NewsJul 17, 2020Data from a large randomized controlled trial in the UK show a benefit from dexamethasone in hospitalized COVID-19 patients, but 2 more studies show no benefit for hydroxychloroquine.

Published in COVID-19

iopac

More from COVID-19More posts in COVID-19 »